Description of Zepbound
- Active Ingredient: Tirzepatide.
- Drug Class: It is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by reducing appetite and slowing down the movement of food through the body, which helps you feel fuller longer and consume fewer calories.
- Indication: It is used as an adjunct to a reduced-calorie diet and increased physical activity for:
- Chronic weight management in adults with obesity or those who are overweight and have at least one weight-related comorbid condition (e.g., high blood pressure, type 2 diabetes).
- Treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
- Form and Administration: Zepbound comes as a liquid solution in a prefilled, single-dose, disposable injection pen or a single-dose vial. It is administered as a subcutaneous injection once weekly into the abdomen, thigh, or upper arm.
- Dosage: The strength is the initial recommended starting dosage, typically injected once weekly for the first four weeks of treatment. This low dose helps the body adjust to the medication and reduces the risk of gastrointestinal side effects. It is not approved as a maintenance dosage. The dose is then gradually increased based on a healthcare provider’s recommendation.
- Common Side Effects: The most common side effects include nausea, diarrhea, constipation, vomiting, abdominal pain, and injection site reactions.

PT-141 (Libido/Sex drive) 10mg - Apoxar
Faran Clomid - Clomiphene Citrate 50mg/10tabs
Mysimba 8 mg/90 mg
Ketotifen 1mg (Removes Clen Side Effects) 1mg/60tabs - Pharmacy Grade
Wegovy 1mg Injection – Powerful Semaglutide Weight Loss Treatment
Nolvadex 20mg - Tamoxifen (Anti-estrogen, PCT) 20mg/50tabs - Apoxar
Mounjaro Weight Loss Injection (15mg)
Ozempic (0.5mg)
HCG - Gonadotropin 5000IU - Apoxar
Fluorobut (Smart Drug) - 4-Fluorophenibut 150mg/50caps - Innovagen
Cytomel T3 25mcg/100tabs - NovoPharm
HCG - Gonadotropin 5000IU - Bayer
Saxenda 


Reviews
There are no reviews yet.